BIO-Europe® 2016: How are regulatory changes affecting early stage R&D in China?

November 25, 2016
Darren Ji, former VP and global head of Asia and emerging markets at Roche, chats with Mike Ward, global director of content for Informa Pharma Intelligence, about current trends disrupting the pharma sector in China. Darren Ji took part in a panel at BIO-Europe® 2016 focused on changes in the Chinese pharma industry. He discusses the recent crackdown on clinical data quality by the China FDA and regulatory changes for early stage R&D in the region.
Previous Video
BIO-Europe® 2016: Vaximm seeks pharma partners for T-cell/checkpoint inhibitor combos
BIO-Europe® 2016: Vaximm seeks pharma partners for T-cell/checkpoint inhibitor combos

Dr. Matthias Schroff, the new CEO of privately-held Swiss vaccines company Vaximm, talks to Mike Ward, glob...

Next Video
BIO-Europe® 2016: Dimerix CEO explains company's different drug combo R&D strategy
BIO-Europe® 2016: Dimerix CEO explains company's different drug combo R&D strategy

Global director of content for Informa Pharma Intelligence, Mike Ward, talks to Kathy Harrison, CEO of Aust...